Dynamic Changes in Myofibroblasts Affect the Carcinogenesis and Prognosis of Bladder Cancer Associated With Tumor Microenvironment Remodeling

YiHeng Du1,2†, YiQun Sui3†, Jin Cao4, Xiang Jiang4, Yi Wang1, Jiang Yu1, Bo Wang1, XIZhi Wang1* and BoXin Xue2*

1Department of Urology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China, 2Department of Urology, The Second Affiliated Hospital of Soochow University, Suzhou, China, 3Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China, 4Department of Pathology, Suzhou Kowloon Hospital, Shanghai Jiaotong University School of Medicine, Suzhou, China

Bladder cancer (BLCA) is a tumor that possesses significant heterogeneity, and the tumor microenvironment (TME) plays an important role in the development of BLCA. The TME chiefly consists of tumor cells and tumor-infiltrating immune cells admixed with stromal components. Recent studies have revealed that stromal components, especially cancer-associated fibroblasts (CAFs), affect immune cell infiltration and modulate the extracellular matrix in the TME of BLCA, ultimately impacting the prognosis and therapeutic efficacy of BLCA. Among the subgroups of CAFs, myofibroblasts (myCAFs) were the most abundant and were demonstrated to play an essential role in affecting the prognosis of various tumors, including BLCA. However, the dynamic changes in myCAFs during carcinogenesis and tumor progression have been less discussed previously. With the help of bioinformatics algorithms, we discussed the roles of myCAFs in the carcinogenesis and prognosis of BLCA in this manuscript. Our study highlighted the pathogenesis of BLCA was accompanied by a decrease in the abundance of myCAFs, revealing potential protective properties of myCAFs in the carcinogenesis of BLCA. Meanwhile, the reduced expressions of myCAFs marker genes were highly accurate in predicting tumorigenesis. In contrast, we also demonstrated that myCAFs regulated extracellular matrix remodeling, tumor metabolism, cancer stemness, and oncological mutations, ultimately impacting the treatment responsiveness and prognosis of BLCA patients. Thus, our research revealed the bimodal roles of myCAFs in the development of BLCA, which may be associated with the temporal change of the TME. The in-depth study of myofibroblasts and the TME may provide potential diagnostic biomarkers and therapeutic targets for BLCA.

Keywords: bladder cancer, tumor microenvironment, myofibroblasts, carcinogenesis, therapy responsiveness
INTRODUCTION

Bladder cancer (BLCA) is a common cancer of the urinary system with two distinct features, frequent recurrence and heterogeneity in tumor progression (Lokeshwar et al., 2020). Clinically, BLCA can be divided into muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC) (Kamoun et al., 2020). Of note, myofibroblasts are present in the vast majority of MIBC sections, suggesting that myofibroblasts play a critical role in the progression and heterogeneity of BLCA. Owing precisely to the highly heterogeneous nature of MIBC, patients with MIBC have limited treatment options and often need to undergo radical cystectomy, which significantly affects patients’ quality of life (Gakis et al., 2017). With the recent development of immunotherapy, immune checkpoint blockade (ICB) therapy is now a guideline-recommended treatment for advanced BLCA when chemotherapy fails (Funt and Rosenberg, 2017). However, ICB therapy still faces many limitations, including multiple adverse effects and unpleasant therapeutic responsiveness (Lopez-Beltran et al., 2021).

The tumor microenvironment (TME) is an intricate system that mainly consists of tumor cells, stromal cells, and tumor infiltrated immune cells (Patnaik et al., 2017). Emerging evidence has shown that stromal components can shape the TME, influence chemotherapy and immunotherapy responsiveness, and promote malignant tumor progression (Yang et al., 2018). Cancer-associated fibroblasts (CAFs) occupy a dominant position in the stromal components of the TME. Recent evidence suggests that CAFs play profound roles in shaping the immune landscape of the TME via ECM-regulated immune cell anchorage and trafficking and via suppression of immune activation (Yu et al., 2020). In addition, CAFs-associated remodeling of the TME also plays a crucial role in the chemosensitivity of tumors (Zhang et al., 2020). Thus, the functions of CAFs in the tumor microenvironment are complicated, and further studies on CAFs are critical in the field of cancer research.

With the rapid development of single-cell RNA sequencing (scRNA-seq) techniques, CAFs are now considered to be classified into different subgroups, including inflammatory CAFs (iCAFs), myofibroblasts (myCAFs), and antigen-presenting CAFs (apCAFs) (Elyada et al., 2019). myCAFs have been shown to promote a more aggressive cancer cell phenotype by both in vivo and in vitro experiments (Otranto et al., 2012). Meanwhile, myCAFs have been demonstrated to greatly impact patients’ prognosis among various types of human cancers (Liu et al., 2016). However, controversy remains, with some studies confirming that animal models of pancreatic cancer after removal of myCAFs exhibit significantly worse prognosis, suggesting that fibroblast reactions could also play a protective role (Ozdemir et al., 2014). Therefore, it is essential to investigate the dynamics of myCAFs to study the temporal alterations in the tumor microenvironment.

In the present study, we comprehensively discussed the roles of myCAFs in the carcinogenesis and progression of BLCA with the help of bioinformatics algorithms and immunohistochemical validations. Our research revealed dual functions of myCAFs that crucially affected the carcinogenesis, prognosis, and therapy responsiveness of BLCA. Further studies on myCAFs may provide potential diagnostic biomarkers and therapeutic targets for BLCA.

MATERIALS AND METHODS

Raw Data Acquisition

The gene transcriptome data of 408 patients with BLCA were downloaded from the TCGA portal (https://portal.gdc.cancer.gov/), 406 patients with complete clinical information were further selected. The average gene expression of the samples from the same patient was calculated using the “limma” package of R software version 4.0.3. Gene expression was transformed into TPM for further analysis. Meanwhile, GEO cohorts (GSE13507 and GSE32894) were obtained from the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/). Gene expression of the TCGA and GEO cohorts was transformed by log2 (expression+1) before normalization by the “Combat” algorithm of the “SVA” package. The integrated cohort (TCGA, GSE13507, and GSE32894) was used for subsequent analysis. The IMvigor210 cohort was obtained from the R package “IMvigor210CoreBiologies” for external validation (Mariathasan et al., 2018). (http://researchpub.gene.com/IMvigor210CoreBiologies/IMvigor210CoreBiologies.tar.gz). The information of the cohorts used in this manuscript was provided in Table 1.

Weighted Gene Co-Expression Network Analysis (WGCNA) and Differentially Expressed Genes (DEGs) Analysis

The “WGCNA” R package was used to identify the genes correlated with normal and tumor tissues for co-expression network analysis. A heatmap displays the values of the correlation between each module and the normal and tumor tissues. The genes with the highest correlations in the modules were selected for subsequent analysis. DEGs were calculated using the Limma package of R software between different groups and were defined as genes with adjusted p-value < 0.05 and |Log2(Fold Change)| >1.

Survival Analysis and Independent Prognostic Factor Screening

Kaplan–Meier (KM) survival analysis with the log-rank test was used to compare the survival differences in the present study. Figures were plotted using the R packages “survival” and “survminer.” The Univariate and multivariate Cox regression analyses were performed to screen the independent risk factors for patients’ overall survival (OS) and disease-free survival (DFS). Due to the different survival information in the integrated BLCA cohort, the survival analysis for OS in this study collected patients from the TCGA and GSE13507 cohorts. The analysis for DFS included patients from the GSE32894 cohort.
TABLE 1 | Information for the BLCA cohorts used in the present study.

| Cohort | GSE13507 | GSE32894 | TCGA-BLCA | IMvigor210 |
|--------|----------|----------|-----------|-----------|
| Type (Number) | NMIBC(103), MIBC(62) | NMIBC(215), MIBC(93) | NMIBC(6), MIBC(401) |         |
| Gender | Female:30, Male:135 | Female:80, Male:228 | Female:107, Male:299 | Female:65, Male:233 |
| Survival outcome | OS | DFS | OS |         |

Consensus Cluster
Consistency analysis of all the samples was conducted using the ‘ConsensusClusterPlus’ package of R software version 4.0.3. The maximum number of clusters was 9, and 80% of the total sample was drawn 50 times, clusterAlg = “km,” distance = “euclidean.” In this study, BLCA patients were clustered into three distinct subgroups based on the gene expression levels of myCAF marker genes, including ACTA2, TAGLN, MYL9, TPM1, and TPM2.

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Pathway Enrichment Analysis
Gene Ontology (GO), which included molecular function (MF), biological pathways (BP), and cellular components (CC), was used for functional annotation. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was used to obtain an analytical study based on DEGs. The “ClusterProfiler” package of R software was used to annotate GO functions and enrich the KEGG pathways.

Calculation of the Cancer Stemness Index
The OCLR algorithm was constructed by Malta et al. to calculate cancer stemness based on mRNA expression and DNA methylation levels (Malta et al., 2018). In this manuscript, we used EREG-mRNAsi and EREG-DNAsi to represent the stemness of each sample. We further corrected the stem cell index by adjusting to the tumor purity and obtained the corrected stem cell index (mRNAsi or DNAsi/TumorPurity). The cancer stemness results of TCGA patients were obtained from the UCSC Xena database (https://xenabrowser.net/datapages/).

Gene Set Variation Analysis and Single-Sample Gene Set Enrichment Analysis (ssGSEA)
Gene set variation analysis (GSVA) is a pathway-based analysis method that provides each sample with an overall pathway or gene set activity score (Hänzelmann et al., 2013). The pathways of the hallmark gene sets were used for GSVA to identify their comprehensive activities. The ssGSEA algorithm is a rank-based method defining a score representing the degree of absolute enrichment of a particular gene set in each sample. We constructed the myCAFs score based on the combined expression of myCAF marker genes, including ACTA2, TAGLN, MYL9, TPM1, and TPM2. The GSVA and ssGSEA processes were conducted by the R Bioconductor package Gene Set Variation Analysis version 3.5. The high and low myCAFs groups were classified based on the medium value of the myCAFs score.

Bladder Cancer Molecular Subtyping
The molecular subtype of BLCA was obtained from previously published articles, which classified BLCA into five subtypes (Robertson et al., 2017) according to molecular expression, mutation, and immune infiltration.

Estimation of Tumor-Infiltrating Immune Cells and Biological Functions
The abundance of the TME components was estimated by the ‘immunedevcon’ (Sturm et al., 2019) R package. The results of four different algorithms, including TIMER (Li et al., 2016), CIBERSORT (Newman et al., 2015), xCELL (Aran et al., 2017), and MCP-COUNTER (Becht et al., 2016), are displayed. Subsequently, scores of biological functions, including lipid metabolism (Wu et al., 2019), energy metabolism (Zhou et al., 2018), DNA repair (Jinjia et al., 2019), senescence-associated secreting phenotype (SASP) (Birch and Gil, 2020), and aging (Cardoso et al., 2018), were acquired through the ssGSEA algorithm.

Calculation of Tumor Immune Dysfunction and Exclusion and Prediction of ICB Treatment Reactiveness
The tumor dysfunction and exclusion scores of each patient were calculated using the TIDE algorithm. Potential ICB response was predicted based on the dysfunction and exclusion score. TIDE uses various gene expression markers to assess two distinct tumor immune escape mechanisms, including tumor-infiltrating cytotoxic T lymphocyte (CTL) dysfunction and exclusion by immunosuppressive factors. Higher TIDE scores indicated poorer efficacy of ICB therapy (Jiang et al., 2018).

Prediction of the Chemotherapeutic Response
We predicted the chemotherapeutic response for each TCGA sample based on the largest publicly available pharmacogenomics database, the Genomics of Drug Sensitivity in Cancer (GDSC), (https://www.cancerrxgene.org). The prediction process was implemented by the R package “pRRophetic,” where the half-maximal inhibitory concentration (IC50) of the samples was estimated by ridge regression (Geleher et al., 2014; Lu et al., 2019).
**Gene Mutation Analysis**
Somatic mutation information was downloaded from the TCGA database and subsequently visualized using the R package “maftools.” The waterfall plot showed mutation data of each gene. The specific mutation types were annotated with different colors at the bottom left of the waterfall plot. The tumor mutation burden (TMB) was estimated as (total mutation/total covered colors at the bottom left of the waterfall plot. The tumor mutation gene. The specific myCAFs marker genes for bladder carcinogenesis. The yellow module of WGCNA was identified as the most related module with tumorigenesis (Figure 1A). A total of 325 up-regulated and 722 down-regulated DEGs were identified by differential analysis (Figure 1B). After intersecting genes in the yellow module of WGCNA with DEGs, we identified five myCAFs marker genes defined by previous single-cell sequencing (Elyada et al., 2019) that were significantly down-regulated in tumor tissues, including ACTA2, MYL9, TAGLN, TPM1, and TPM2 (Figures 1C,D). To clarify the impact of these genes on the prognosis of BLCA, we applied the KM survival analysis, with the results showing that high expression of these genes impaired the OS (Figure 1E) and DFS (Figure 1F) of BLCA patients. These results indicated the dual roles of myCAFs marker genes in tumorigenesis and BLCA prognosis.

**Immunohistochemical Analysis and Scoring**
Forty postoperative BLCA sections from 2016 to 2021 were recruited for IHC analysis with the approval of the institutional ethics committee. The patients’ clinical information is listed in the following table (Table 2). The BenchMark GX automatic immunohistochemical staining system (Roche, Switzerland) with the Opti View DAB Detection Kit (Ventana, USA) was used to detect ACTA2 (Abcam, catalog number: ab7817, 1:250) expression in this study. The primary antibodies were visualized using a horseradish peroxidase-labeled secondary antibody. Hematoxylin was applied for counterstaining, whereas Bluing Reagent was applied for post counterstaining. The mean integrated optical density (IOD) values of positive protein expression was calculated by Image-Pro Plus 6.0.

**Statistical Analysis**
Principal component analysis (PCA) confirmed the distinct distribution of the clusters gained from the consensus analysis. The Wilcoxon test was used to examine the differences between variables of the two groups. Furthermore, the Kruskal–Wallis test (non-normal distribution) or one-way ANOVA (normal distribution) was used to analyze statistically significant differences for the variables of more than two groups. The Spearman correlation test examined the relationship between two different elements. The Receiver operating characteristic (ROC) curves were used to determine the predictive accuracy of myCAFs marker genes for bladder carcinogenesis. A two-sided $p$ value < 0.05 was considered statistically significant. All statistical analyses were performed using R language v4.0.3.

**RESULTS**

Five myCAFs Marker Genes Were Identified to Be Associated With the Pathogenesis and Prognosis of BLCA
We applied WGCNA and DEGs analysis between normal and BLCA samples to screen for genes potentially associated with bladder carcinogenesis. The yellow module of WGCNA was identified as the most related module with tumorigenesis (Figure 1A). A total of 325 up-regulated and 722 down-regulated DEGs were identified by differential analysis (Figure 1B). After intersecting genes in the yellow module of WGCNA with DEGs, we identified five myCAFs marker genes defined by previous single-cell sequencing (Elyada et al., 2019) that were significantly down-regulated in tumor tissues, including ACTA2, MYL9, TAGLN, TPM1, and TPM2 (Figures 1C,D). To clarify the impact of these genes on the prognosis of BLCA, we applied the KM survival analysis, with the results showing that high expression of these genes impaired the OS (Figure 1E) and DFS (Figure 1F) of BLCA patients. These results indicated the dual roles of myCAFs marker genes in tumorigenesis and BLCA prognosis.

### TABLE 2 | Clinical information for BLCA patients with IHC analysis.

| Characteristics | Age | Gender | T Stage | N stage | M Stage | Grade |
|-----------------|-----|--------|---------|---------|---------|-------|
|                 | ≤65 | >65    | Male    | Female  | Ta-T1   | T2-T4 |
| Number          | 19  | 21     | 30      | 10      | 26      | 14    |
|                 | 38  | 2      | 37      | 3       | 32      | 8     |

**myCAFs Abundance Was an Independent Risk Factor for Patients’ OS and DFS**
To better quantify the abundance of myCAFs, we constructed a myCAF score by the ssGSEA algorithm based on the combined expression levels of the five myCAF marker genes. High myCAFs
score significantly shortened patients’ OS (high vs. low, \( p < 0.001 \)) and DFS (high vs. low, \( p < 0.001 \)) (Figure 3A) and acted as an independent risk factor for OS (multivariate Cox regression, \( p = 0.049 \)) (Figure 3B) and DFS (multivariate Cox regression, \( p = 0.031 \)) (Table 4). The correlation analysis between myCAFs scores and clinical characteristics of BLCA patients revealed significant differences in myCAFs scores between subgroups of myCAFs, between BLCA patients with

FIGURE 1 | WGCNA and DEGs analysis identified five marker genes of myCAFs that showed bimodal functions on bladder cancer carcinogenesis and prognosis. (A) WGCNA indicated the yellow module was the most correlated module with bladder carcinogenesis, with a correlation efficiency (Gene significance to module membership) of 0.83. (B) Volcano plot displayed the differentially expressed genes between normal and tumor samples with adjusted \( p \)-value < 0.05 and |Log2(Fold Change)| > 1. (C,D) The intersection of WGCNA and DEG analysis in the integrated cohort identified the expression of five myCAFs related genes, including ACTA2, TAGLN, MYL9, TPM1, and TPM2, were significantly down-regulated in tumor tissue \( (p < 0.001) \). (E,F) KM survival analysis revealed that patients with high expression of ACTA2, TAGLN, MYL9, TPM1, and TPM2 owned shortened OS \( (p < 0.001) \) (panel E) and DFS \( (p < 0.001) \) (panel F), *** \( p < 0.001 \).
FIGURE 2 | Consensus clusters identified three subgroups of BLCA patients showing significant differences in clinical pathological and tumor microenvironment features. (A) BLCA patients in the integrated cohort were classified into three distinct clusters based on the myCAFs related gene expressions. (B) KM survival analysis indicated a significant OS difference between the three clusters \((p = 0.002)\), with patients of cluster A showing the lowest medium survival interval. (C) Patients’ DFS was significantly lower in cluster A and B than that in cluster C \((p < 0.001)\). (D) The heatmap demonstrated the association of BLCA subgroups with T-stage, age, and gender, suggesting that subgroups with high levels of myCAFs have a higher proportion of more advanced BLCA patients \((p < 0.001)\). (E) Principal component analysis confirmed the scattered distribution of CAFs related gene expressions between the three clusters. (F,G) The 60 common differentially expressed genes between the three clusters were significantly enriched in extracellular matrix remodeling related processes, including extracellular structure organization, ECM-receptor interaction, and Focal adhesion.
different ages and T-stages (Figure 3C). These results suggested that advanced BLCA tended to own higher myCAFs abundance. Meantimes, we found that the subtypes with higher myCAFs scores took a higher proportion in T3-T4 patients than in T2 patients, laterally suggesting the potential correlation of myCAFs abundance with the T-stage of BLCA patients (Figure 3D). We also observed that the patient’s age crucially altered the myCAFs score, indicating that senescence impacts the abundance of myCAFs. To further discuss the effect of myCAFs on survival in different subgroups of BLCA patients, we conducted subgroup survival analysis and found that the myCAFs level had a significant impact on the OS and DFS of BLCA patients in several subgroups, especially in young (age < 65) and male patients (Figures 3E,F).

myCAFs regulated in T Cell Infiltration and Immune Response, Further Influencing the Immunotherapy Responsiveness of BLCA Patients

With the TIMER, CIBERSORT, and MCP-COUNTER algorithms, we found that tumors with high myCAFs scores had higher CD8+ T cell infiltration and possessed elevated levels of immunosuppressive cells such as M2 macrophages (Figure 4A). myCAFs scores were also correlated with tumor microenvironment scores provided by xCELL, especially stromal scores. These results suggest that the abundance of myCAFs in stromal components may increase the infiltration of CD8+ T cells and affect the M2 polarization of macrophages. Further analysis of the immune processes associated with myCAFs revealed that myCAFs scores were significantly positively correlated with the levels of various immune checkpoint molecules (Figure 4B). Tumors with high myCAFs scores had higher CCR, checkpoint, cytotoxicity, HLA, MHC, and proinflammatory activities (Figure 4C). The TIDE algorithm further revealed that myCAFs scores significantly correlated with T cell exclusion and dysfunction (Figure 4D). These results indicated that myCAFs could induce and sequester CD8+ T cells in the tumor microenvironment, hinder their infiltration into the tumor tissue, and ultimately lead to T cell dysfunction, resulting in immune evasion. Subsequent predictions of response to immune checkpoint inhibitor therapy by the TIDE algorithm confirmed these inferences, showing that patients with high myCAFs scores exhibited lower responsiveness to immune checkpoint therapy (Figure 4E). Immune checkpoint responsiveness results from the IMvigor210 cohort further confirmed the predictions of the TIDE algorithm (Figure 4F). We also validated the characteristics of myCAFs scores in patients with different T cell infiltration features in the IMvigor210 cohort. Specifically, myCAFs scores were higher in the inflamed and excluded phenotypes than in the desert phenotype (Figure 4G).

myCAFs Were Correlated With Tumor Metabolic Features, Senescence-Associated Secreting Phenotype, and Cancer Stemness, Influencing the Responsiveness of BLCA Patients to Chemotherapy

We further analyzed the metabolic characteristics associated with myCAFs. We found that energy, lipid metabolism, fatty acid metabolism, and adipogenesis activities were significantly reduced in tumors with high myCAFs. In contrast, SASP and senescence-related gene expression were significantly more active in tumors with high myCAFs. After GSVA, we found that tumors with high myCAFs exhibited stronger angiogenesis and myogenesis, more elevated hypoxia, and lower oxidative phosphorylation levels. These results fully suggested that remodeling of the tumor microenvironment by myCAFs could occur through multiple pathways and finally result in a hypoxia- and nutrition-deprived tumor microenvironment. In addition, myCAFs could also affect several signaling pathways related to tumor cell stemness, such as the STAT3 (Wang et al., 2018), KRAS (Yoon et al., 2019), and Notch (Yang et al., 2020) signaling pathways, suggesting that the abundance of myCAFs may affect tumor stemness (Figures 5A,B). We then performed correlation analysis between myCAFs and tumor stemness by two different scoring algorithms, the mRNA stemness index (EREG-mRNAsi) and the DNA stemness index (EREG-DNAsi). We corrected the above index based on tumor purity, considering the influence of stromal components (Stemcell index/TumorPurity). The results showed that the myCAFs score had a significant positive correlation with the tumor stemness index, suggesting that tumor stemness was more robust in patients with higher myCAFs scores (Figure 5C). Among the sensitivity of chemotherapeutic drugs obtained by the “pRRophetic” package, we found that patients with higher myCAFs scores tended to respond to cisplatin-based chemotherapy. In contrast, myCAFs abundance significantly impacted patient sensitivity to two commonly used chemotherapeutic drugs for BLCA, gemcitabine and methotrexate (Figure 5D).

myCAFs Were Associated With Tumor Mutation Burden and Oncogenic Mutations, Especially FGFR3 and the RTK-RAS Signaling Pathway

After analyzing the gene mutation profile of the TCGA BLCA cohort by the “maftools” package, we combined the gene mutation information with myCAFs scores and found that myCAFs scores conformed to show a significant negative correlation with tumor mutation burden (TMB) (Figure 6A).
In addition, myCAFs score combined with TMB had a more substantial effect on patients’ OS (Figure 6B), and the mutation information of the IMvigor210 cohort further confirmed the negative correlation between myCAFs abundance and TMB (Figure 6C). In addition, the abundance of myCAFs had a significant effect on the RTK-RAS signaling pathway (Figure 6D) and FGFR3 mutation frequency (Figure 6E), showing that tumors with high myCAFs scores often possessed lower RTK-RAS signaling pathways and FGFR3 mutation frequencies.

**FIGURE 3** | The myCAFs score was significantly correlated with patients’ prognosis and clinical-pathological features. (A) Patients with high myCAFs scores showed significant impaired OS \( p < 0.001 \) and DFS \( p < 0.001 \). (B) The myCAFs score acted as an independent risk factor for patients’ OS revealed by multivariate Cox regression analysis \( p = 0.049 \). (C) The myCAFs score was significantly correlated with patients’ myCAFs cluster, age, and T-stage. (D) Significant differences in myCAFs scores were found among molecular subtypes of BLCA, with a higher proportion of myCAFs-rich molecular subtypes in more advanced BLCA \( p < 0.001 \). (E) Subgroup survival analysis in TCGA and GSE13507 cohorts showed that patients with high myCAFs scores tended to own impaired OS, especially patients with male \( p < 0.001 \) and age less than 65 \( p < 0.001 \). (F) Subgroup survival analysis on patients’ DFS in the GSE32894 cohort also confirmed high myCAFs score shortened DFS in patients with male \( p < 0.001 \) and age less than 65 \( p < 0.001 \). *** \( p < 0.001 \), ** \( p < 0.01 \), * \( p < 0.05 \).
IHC Analysis Validated the Dynamics of myCAFs During Tumor Development

Combined with the above bioinformatics analysis, we found a dynamic change in myCAFs abundance during the development of BLCA. To validate this phenomenon, we further compared the expression levels of the myCAFs marker genes in paired BLCA and normal paraneoplastic samples in the TCGA cohort (Figure 7A). The results confirmed the reduced expression of the myCAFs marker genes in tumor tissues. ROC analysis indicated highly diagnostic accuracy of the myCAFs marker genes in distinguishing tumors from normal bladder tissues, especially ACTA2 (Figure 7B). Through IHC assay, we verified the reduced ACTA2 expression levels in tumor tissues compared with the adjacent normal mucosa, indicating a decreased myCAFs abundance in BLCA tissue (Figure 7C). Further analysis of ACTA2 in BLCA sections with different stages revealed that ACTA2 expression levels were significantly elevated in T2 (MIBC without external bladder invasion) and T3-T4 BLCA (MIBC with external bladder invasion) (Figure 7D). Thus, we summarize the characteristics of changes in ACTA2 expression during BLCA carcinogenesis and progression in our recruited postoperative sections (Figure 7E), showing similar features to the dynamic changes in the fraction of myCAFs in our bioinformatics analysis cohorts (TCGA, GSE13507, and GSE32894) (Figure 7F).

DISCUSSION

BLCA is the fourth most common cancer among the male population (Kaneko and Li, 2018). The incidence rate of BLCA is higher in men, three to five times higher than that in women. It has a worldwide incidence and mortality of 330,000 and 123,000, respectively (Davis et al., 2018). Therefore, BLCA is a significant burden on global public health. Most BLCA are urothelial carcinomas and are classified as either NMIBC or MIBC because of the distinct implications on patient management. Radical cystectomy is still the mainstay treatment for MIBC. Treatments for high-grade muscle invasive and metastatic BLCA have not advanced beyond gemcitabine and cisplatin combined chemotherapy. Recently, ICB therapy has opened the possibility of immunotherapy for BLCA, especially for muscle-invasive and metastatic BLCA, when chemotherapy fails.

While cancer originates from the accumulation of mutations within cancer cells, cancer progression and therapy responsiveness are strongly modulated by the surrounding stromal cells in the tumor microenvironment (Sahai et al., 2020). The last decades have witnessed a significant research trend towards CAFs. It is now believed that CAFs regulate cancer proliferation and metastasis through growth factor production, synthesis, and remodeling of the extracellular matrix (ECM). Recently, there has also been a growing understanding of the ability of CAFs to regulate the immune system. Targeting CAFs, by altering their number, subtype, or function is being explored to improve cancer therapy (Sahai et al., 2020). With the advancement of research techniques in recent years, many controversies have emerged in the study of CAFs, including the different effects of CAFs on tumors.

While most previous reports showed a significant tumor-promoting effect of CAFs, studies of CAFs have also identified the antitumor roles of CAFs (Özdemir et al., 2014). Evidence proposed that tumor stroma played a bimodal role in cancer development, impeding neoplastic growth in normal tissue while encouraging migration and tumor growth during tumor progression. The heterogeneity of CAFs allows them to comprise multiple subgroups, including tumor-promoting and tumor-suppressing CAFs (Schauer et al., 2011). As the fibroblasts are very heterogeneous and highly plastic, temporal changes of the tumor microenvironment could dramatically affect the dynamics of fibroblasts during cancer development. It has been demonstrated that there is a process of interconversion between different subgroups of CAFs and that the conversion of cancer-inhibiting to cancer-promoting CAFs may accompany the development of BLCA (Li B. et al., 2021). A recent study also demonstrated that CAFs in lung metastases are transcriptionally dynamic and plastic, revealing stage-specific gene signatures of CAFs that imply functional tasks to remodel the tumor microenvironment, including extracellular matrix remodeling, stress response, and shaping the inflammatory microenvironment (Shani et al., 2021). By investigating the effects of myofibroblasts in early lesions in breast cancer development and progression, Betul G et al. revealed the phenotypic and functional characteristics of CAFs in preneoplastic lesions, further underlining the importance of temporal changes in CAFs during cancer progression (Gok Yavuz et al., 2018). Freja A et al. demonstrated that multiple subpopulations of CAFs co-exist in murine breast cancer and that the abundance and dynamics for each marker differ depending on tumor type and time (Venning et al., 2021). In the present article, we also found evidence with the bioinformatics analysis supporting that myCAFs played dual functions within the carcinogenesis and progression of BLCA, further emphasizing the significance of the temporal change in tumor microenvironment on both the tumor and stromal cells. Meanwhile, Our study also found that the pathogenesis of epithelial tumors like BLCA was accompanied by a significant decrease in fibroblast content, resulting in significantly lower expression levels of marker genes for myCAFs such as ACTA2.

### TABLE 4 | Univariate and multivariate Cox regression of myCAFs for patient DFS.

| Characteristics        | HR   | HR.95 L | HR.95H | p-value |
|------------------------|------|---------|--------|---------|
| **Univariate Cox regression** |      |         |        |         |
| Gender                 | 1.538 | 0.577   | 4.100  | 0.389   |
| Age                    | 0.551 | 0.251   | 1.210  | 0.137   |
| T-stage                | 45.067| 10.617  | 191.473| <0.001  |
| myCAFs                 | 144.304| 10.964  | 1899.241| <0.001  |
| **Multivariate Cox regression** |      |         |        |         |
| Gender                 | 2.232 | 0.796   | 6.255  | 0.127   |
| Age                    | 0.638 | 0.276   | 1.464  | 0.287   |
| T-stage                | 30.523| 6.976   | 133.555| <0.001  |
| myCAFs                 | 20.181| 1.320   | 308.566| 0.031   |
However, it does not mean that activated fibroblasts are more deficient in BLCA than normal tissues. Previous studies have confirmed that the proportion of myCAFs in BLCA was still elevated compared to normal paraneoplastic tissues (Li B. et al., 2021). Therefore, it is critical to discuss the changes in fibroblasts during the development of BLCA in terms of their absolute content and the ratio of different CAFs subpopulations.

**FIGURE 4** | Relationship between myCAFs score and the immune landscape of BLCA patients. (A) The TIMER, CIBERSORT, xCELL, and MCP-COUNTER algorithms showed significantly higher CD8+ T cells ($p < 0.001$) and M2 macrophages ($p < 0.001$) in the high myCAFs group. (B) The myCAFs score was significantly positively correlated with the expression levels of multiple immune checkpoint-related genes, including CD274 ($R = 0.21, p < 0.001$), PDCD1 ($R = 0.28, p < 0.001$), CTLA4 ($R = 0.40, p < 0.001$), PDCD1LG2 ($R = 0.45, p < 0.001$), HAVCR2 ($R = 0.47, p < 0.001$), and LAG3 ($R = 0.33, p < 0.001$). (C) Immune-related functions, including CCR ($p < 0.001$), checkpoint ($p < 0.001$), cytotoxic activity ($p < 0.001$), HLA ($p < 0.001$), inflammation-promoting ($p < 0.001$), MHC_class_I ($p < 0.001$), and para inflammation ($p < 0.001$) were significantly higher in patients with high myCAFs scores. (D) The myCAFs score was positively correlated with T cell dysfunction ($R = 0.57, p < 0.001$) and exclusion score ($R = 0.53, p < 0.001$) gained from the TIDE algorithm. (E) TIDE algorithm predicts that patients with high myCAFs scores are more likely to be unresponsive to ICB treatment ($p < 0.001$). (F) The results of the IMvigor210 immunotherapy cohort confirmed the lower responsive rate of high myCAFs score patients. (G) myCAFs scores were higher in excluded ($p < 0.05$) and inflamed ($p < 0.05$) phenotype than that in desert phenotype. ***$p < 0.001$, **$p < 0.01$, *$p < 0.05$, ns: not significant.
This present article identified five myCAFs marker genes that showed highly similar expression patterns and impact on BLCA patients’ prognosis, including ACTA2, TAGLN, MYL9, TPM1, and TPM2. Three different subgroups of BLCA patients based on the expression of these genes were revealed through systematic bioinformatics analysis. Patients with distinct myCAFs levels exhibited diverse tumor microenvironment features with altered infiltration of CD8 T cells and the polarization of M2 macrophages, further bringing differences in patients’ prognosis and treatment responses. With further verification of the TIDE algorithm and the IMvigor210 immunotherapy cohort, our results highlighted that the therapy targeting myCAFs might benefit patients’ therapy responsiveness and prognosis. Meantime, our study also indicated a crucial effect of senescence on the extracellular matrix and fibroblasts with elder patients possessing higher myCAFs abundances (Fane and Weeraratna, 2020), suggesting that aging-related factors also need to be adequately addressed in the study of CAFs.

In the present study, we also found that myCAFs were significantly correlated with the mutation frequency of FGFR3 in TCGA BLCA patients, showing that patients with high FGFR3 mutations possessed lower myCAFs abundance. We further revealed a negative correlation between myCAFs content and tumor mutation burden, suggesting that BLCA with high myCAFs content has a lower TMB. Since previous studies indicated that a low TMB is detrimental to the immune system’s recognition of tumor cells and affects the immunotherapeutic response, our results suggested that the effect of myCAFs on therapeutic responsiveness might also be related to tumor mutations (Sholl et al., 2020).

Predictive models based on bioinformatics analysis are widely available in the field of BLCA research, and many of them show high predictive accuracy (Abudurexiti et al., 2019; Li Z. et al., 2021; Du et al., 2021). However, there are still fewer diagnostic models for predicting the carcinogenesis of BLCA. In the present study, we constructed a myCAFs score that showed potential in distinguishing the pathogenesis of bladder cancer. Meanwhile, our myCAFs score has a significant predictive value for OS and DFS in BLCA. However, our prediction model did not show a considerable advantage in predictive accuracy on patients’ prognoses compared with other prognostic models. The main reason is that our myCAFs score was not constructed by the Cox regression model but by the ssGSEA algorithm. Precisely on this basis,
our myCAFs can reflect the myCAFs content in each tumor sample more realistically than other prediction models, validated by the high correlation of our myCAFs score with the CAFs score calculated by the MCP-COUNTER algorithm (Figure 4A). At the same time, the ssGSEA algorithm integrates the combined expression of the five genes used for myCAFs score construction, leading to a high correlation of the myCAFs score with the expression levels of these five genes. In clinical applications, we can even detect one of these genes, especially ACTA2, to represent the myCAFs score, which is convenient for clinical applications and confirmed by our immunohistochemical experiments.

With our myCAFs score, we deeply explored the dynamic change of myCAFs during BLCA carcinogenesis and...
progression, suggesting that fibroblasts may play multiple roles in the process of tumor development in reaction to the time-dependent tumor microenvironment. However, our results were limited by the lack of deconvoluting algorithms that could precisely identify the accurate subgroups of CAFs in bulk sequencing. Further verification by scRNA-seq and experimental assays are required for discussing the temporal change of CAFs.
Meantime, the prediction of therapy responsiveness in this manuscript mainly depended on bioinformatics algorithms and should be verified by further experimental and clinical research. In addition, we need a larger sample size of BLCA sections to validate the immunohistochemical results of this study.

CONCLUSION

Our results revealed the dynamic changes in myCAFs abundance in the development of BLCA and highlighted the TME remodeling property of myCAFs, which further impacted BLCA patients’ therapy responsiveness and prognosis. The in-depth study of myofibroblasts can help explore the role of fibroblasts in the development of BLCA and provide possible diagnostic markers for predicting bladder carcinogenesis and potential therapeutic targets for BLCA treatment.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article supplementary material.

REFERENCES

Abudurexiti, M., Xie, H., Jia, Z., Zhu, Y., Zhu, Y., Shi, G., et al. (2019). Development and External Validation of a Novel 12-Gene Signature for Prediction of Overall Survival in Muscle-Invasive Bladder Cancer. Front. Oncol. 9, 856. doi:10.3389/fonc.2019.00856

Aran, D., Hu, Z., and Butte, A. J. (2017). xCell: Digitally Portraying the Tissue Cellular Heterogeneity Landscape. Genome Biol. 18 (1), 220. doi:10.1186/s13059-017-1349-1

Becth, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., et al. (2016). Estimating the Population Abundance of Tissue-Infiltrating Immune and Stromal Cell Populations Using Gene Expression. Genome Biol. 17 (1), 218. doi:10.1186/s13059-016-1070-5

Birch, J., and Gil, J. (2020). Senescence and the SASP: many Therapeutic Avenues. Genes Dev. 34 (23-24), 1565–1576. doi:10.1101/gad.343129.120

Cardoso, A. L., Fernandes, A., Aguilar-Pimentel, J. A., de Angelis, M. H., Guedes, J. R., Brito, M. A., et al. (2018). Towards Frailty Biomarkers: Candidates from Genes and Pathways Regulated in Aging and Age-Related Diseases. Ageing Res. Rev. 47, 214–277. doi:10.1016/j.arr.2018.07.004

Davis, R. M., Kiss, B., Trivedi, D. R., Metzner, T. J., Liao, J. C., and Gambhir, S. S. (2018). Surface-Enhanced Raman Scattering Nanoparticles for Multiplexed Imaging of Bladder Cancer Tissue Permeability and Molecular Phenotype. ACS Nano 12 (10), 9669–9679. doi:10.1021/acsnano.8b03217

Du, Y., Wang, B., Jiang, X., Cao, J., Yu, J., Wang, Y., et al. (2021). Identification and Validation of a Stroma EMT Related LncRNA Signature as a Potential Marker to Predict Bladder Cancer Outcome. Front. Oncol. 11, 620674. doi:10.3389/fonc.2021.620674

Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., et al. (2019). Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Disov. 9 (8), 1102–1123. doi:10.1158/2159-8290.cd-19-0094

Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., et al. (2019). Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Disov. 9 (8), 1102–1123. doi:10.1158/2159-8290.cd-19-0094

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethics Committee of Suzhou Kowloon Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

YD and YS contributed equally to this manuscript. YD and BX designed the whole study. YD participated in bioinformatics and statistical analysis. YS, XJ, and JC performed the immunohistochemistry analysis and the corresponding statistical analysis. YW and JY made the manuscript and figure editing. BW and XW revised the manuscript. XW and BX provided administrative support. All the authors read and approved the final version of the manuscript.

FUNDING

This study was funded by the Basic Research on Medical and Health Application of Suzhou Municipal Science and Technology Bureau (Grant number: SYS2020076 and SKJY2021031) and the Pre research Fund of the Second Affiliated Hospital of Soochow University (Grant number: SDFEYQN 1901).

Fane, M., and Weeraratna, A. T. (2020). How the Ageing Microenvironment Influences Tumour Progression. Nat. Rev. Cancer 20 (2), 89–106. doi:10.1038/s41568-019-0222-9

Funl, S. A., and Rosenberg, J. E. (2017). Systemic, Perioperative Management of Muscle-Invasive Bladder Cancer and Future Horizons. Nat. Rev. Clin. Oncol. 14 (4), 221–234. doi:10.1038/nrclinonc.2016.188

Gakis, G., Black, P. C., Bochner, B. H., Bjoerjjan, S. A., Stenzl, A., Thalmann, G. N., et al. (2017). Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy. Eur. Urol. 71 (4), 545–557. doi:10.1016/j.eururo.2016.09.035

Gelehrer, P., Cox, N. J., and Huang, R. (2014). Clinical Drug Response Can Be Predicted Using Baseline Gene Expression Levels and In Vitro Drug Sensitivity in Cell Lines. Genome Biol. 15 (3), R47. doi:10.1186/gb-2014-15-3-r47

Gok, Yavuz, B., Gunaydin, G., Kosemehmetoglu, K., Karakoc, D., Ozgor, F., and Guc, B. (2018). The Effects of Cancer-Associated Fibroblasts Obtained from Atypical Ductal Hyperplasia on Anti-tumor Immune Responses. Breast J. 24 (6), 1099–1101. doi:10.1111/bj.13139

Hänzelmann, S., Castelo, R., and Guinney, J. (2013). GSVa: Gene Set Variation Analysis for Microarray and RNA-Seq Data. BMC Bioinformatics 14, 7. doi:10.1186/1471-2105-14-7

Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., et al. (2018). Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response. Nat. Med. 24 (10), 1550–1558. doi:10.1038/s41591-018-0136-1

Jinjia, C., Xiaoyu, W., Hui, S., Wenhua, L., Zhe, Z., Xiaodong, Z., et al. (2019). The Use of DNA Repair Genes as Prognostic Indicators of Gastric Cancer. J. Cancer 10 (20), 4866–4875. doi:10.7150/jca.31062

Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., et al. (2020). A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. Eur. Urol. 77 (4), 420–433. doi:10.1016/j.eururo.2019.09.006

Kaneko, S., and Li, X. (2018). X Chromosome Protects against Bladder Cancer in Females via a KDM6A-dependent Epigenetic Mechanism. Sci. Adv. 4, eaar5598. doi:10.1126/sciadv.aar5598

Li, B., Pei, G., Yao, J., Ding, Q., Jia, P., and Zhao, Z. (2021). Cell-type Deconvolution Analysis Identifies Cancer-Associated Myofibroblast Component as a Poor
Liu, L., Liu, L., Yao, H. H., Zhu, Z. Q., Ning, Z. L., and Huang, Q. (2016). Stromal Fibroblasts Are Associated with Poor Prognosis in Solid Cancers: A Meta-Analysis of Published Studies. *Plos One* 11, e0159947. doi:10.1371/journal.pone.0159947

Lokeshwar, V. B., Moreira, D. S., Hasanali, S. L., Yates, T. J., Hupe, M. C., Knapp, J., et al. (2020). A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer. *Clin. Cancer Res.* 26 (13), 3455–3467. doi:10.1158/1078-0432.crr-19-2912

Lopez-Beltran, A., Cimadamore, A., Blanca, A., Massari, F., Landon-Brace, N., Gehring, M. P., et al. (2021). Cabozantinib Eradicates Advanced Murine Prostate Cancer. *Cell Death & Disease* 12 (5), 453–457. doi:10.1038/s41419-020-0219-7

Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., et al. (2018). Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. *Cell* 173 (2), 338–354.e15. doi:10.1016/j.cell.2018.03.034

Marthasaran, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., et al. (2018). TGFβ Attenuates Tumour Response to PD-L1 Blockade by Contributing to Exclusion of T Cells. *Nature* 554 (7693), 544–548. doi:10.1038/nature25501

Newman, O. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., et al. (2017). Immunologic and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. *Cell Cancer Cell.* 25 (6), 719–734. doi:10.1016/j.ccr.2014.04.005

Patiña, A., Swanson, K. D., Cuizmadia, E., Solanki, A., Landon-Brace, N., Gehring, M. P., et al. (2017). Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. *Cancer Discov.* 7 (7), 750–765. doi:10.1158/2159-8290.cd-16-0778

Robertson, A. G., Kim, J., Al-Ahmadi, H., Bellmunt, J., Guo, G., Cherniack, A. D., et al. (2017). Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. *Cell* 171 (3), 540–556.e25. doi:10.1016/j.cell.2017.09.007

Shah, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeland, M., Evans, R. M., et al. (2020). A Framework for Advancing Our Understanding of Cancer-Associated Fibroblasts. *Nat. Rev. Cancer* 20 (3), 174–186. doi:10.1038/s41568-019-0238-1

Schauer, I. G., Sood, A. K., Mok, S., and Liu, J. (2011). Cancer-associated Fibroblasts and Their Putative Role in Potentiating the Initiation and Development of Epithelial Ovarian Cancer. *Neoplasia* 13 (5), 393–405. doi:10.1093/neo.101720

Shani, O., Raz, Y., Monteran, L., Scharf, Y., Levi-Galibov, O., Megides, O., et al. (2021). Evolution of Fibroblasts in the Lung Metastatic Microenvironment Is Driven by Stage-specific Transcriptional Plasticity. *Elife* 10, e60745. doi:10.7554/eLife.60745

Sholl, I. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., et al. (2020). The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. *J. Thorac. Oncol.* 15 (9), 1409–1424. doi:10.1016/j.jtho.2020.05.019

Sturm, G., Finotello, F., Petiprez, F., Zhang, J. D., Baumbach, J., Fridman, W. H., et al. (2019). Comprehensive Evaluation of Transcriptome-Based Cell-type Quantification Methods for Immune-Oncology. *Bioinformatics* 35 (14), i436–i445. doi:10.1093/bioinformatics/btz363

Venning, F. A., Zornhagen, K. W., Wullkopf, L., Sjölund, J., Rodríguez-Cupello, C., Kjellman, P., et al. (2021). Deciphering the Temporal Heterogeneity of Cancer-Associated Fibroblast Subpopulations in Breast Cancer. *J. Exp. Clin. Cancer Res.* 40 (1), 175. doi:10.1186/s13046-021-01944-4

Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., et al. (2018). JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. *Cell Metab.* 27 (1), 136–150. e5. doi:10.1016/j.cmet.2017.11.001

Wu, F., Zhao, Z., Chai, R. C., Liu, Y. Q., Li, G. Z., Jiang, H. Y., et al. (2019). Prognostic Power of a Lipid Metabolism Gene Panel for Diffuse Gliomas. *J. Cel Mol Med* 23 (11), 7741–7748. doi:10.1111/jcmm.14647

Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., et al. (2020). Targeting Cancer Stem Cell Pathways for Cancer Therapy. *Surg Translact Target. Ther.* 5 (1), 8. doi:10.1038/s41392-020-0210-5

Yang, Y., Bai, Y., He, Y., Zhao, Y., Chen, J., Ma, L., et al. (2018). PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer. *Clin. Cancer Res.* 24 (4), 834–846. doi:10.1158/1078-0432.ccr-17-2006

Yoon, C., Till, J., Cho, S.-J., Chang, K. K., Lin, J.-x., Huang, C.-m., et al. (2019). KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-To-Mesenchymal Transition to Cancer Stem-like Cells and Promotes Metastasis. *Mol. Cancer Res.* 17 (9), 1945–1957. doi:10.1158/1541-7786.mcr-19-0077

Yu, M., Guo, G., Huang, L., Deng, L., Chang, C.-S., Achyut, B. R., et al. (2020). CD73 on Cancer-Associated Fibroblasts Enhanced by the A2B-Mediated Feedforward Circuit Enforces an Immune Checkpoint. *Nat. Commun.* 11 (1), 515. doi:10.1038/s41467-019-14060-x

Zhang, H., Deng, T., Liu, R., Ning, T., Yang, H., Liu, D., et al. (2020). CAF Secreted miR-522 Suppresses Ferroptosis and Promotes Acquired Chemo-Resistance in Gastric Cancer. *Mol. Cancer* 19 (1), 43. doi:10.1186/s12943-020-01168-8

Zhou, Z., Huang, R., Chai, R., Zhou, X., Hu, Z., Wang, W., et al. (2018). Identification of an Energy Metabolism-Related Signature Associated with Clinical Prognosis in Diffuse Glioma. *Aging* 10 (11), 3185–3209. doi:10.18632/aging.101625

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2022 Du et al. Myofibroblasts Affect Bladder Cancer Development**